TACSTD2 and breast cancer: Drugs that act on cathepsins and induce partial or massive LMP are recently investigated as nanotechnological therapeutic targets.23 TAN as a single nanodepot holds a promising combination of adjuvant chemotherapeutic agent (4OHT), lysosomotropic agent (AuNcgs), MAb (Anti-TROP2 Ab) and an immunomodulating sulfated polysaccharide (MR) for dual targeted combination therapy of breast cancer.